Cargando…

Effects of Metformin on COVID-19 Patients with Type 2 Diabetes: A Retrospective Study

PURPOSE: The pandemic of coronavirus disease 2019 (COVID-19) has highlighted the intricate relationship between underlying conditions and death. We designed this study to determine whether metformin therapy for type 2 diabetes mellitus (T2D) is associated with low in-hospital mortality in patients h...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Ziyu, Gao, Yanxiang, Xie, Enmin, Ye, Zixiang, Li, Yike, Zhao, Xuecheng, Shen, Nan, Zheng, Jingang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10461736/
https://www.ncbi.nlm.nih.gov/pubmed/37645237
http://dx.doi.org/10.2147/DMSO.S417925
Descripción
Sumario:PURPOSE: The pandemic of coronavirus disease 2019 (COVID-19) has highlighted the intricate relationship between underlying conditions and death. We designed this study to determine whether metformin therapy for type 2 diabetes mellitus (T2D) is associated with low in-hospital mortality in patients hospitalized for COVID-19. MATERIALS AND METHODS: This was a retrospective study including patients with COVID-19 and T2D in Wuhan, from February 4th to April 11th, 2020. Patients were divided into two groups according to metformin exposure. The hazard ratio (HR) of COVID-19-related mortality and invasive mechanical ventilation was estimated using Cox regression. RESULTS: There were 571 T2D patients among the 4330 confirmed COVID-19 patients. Of those patients, 241 received metformin therapy. The in-hospital mortality and invasive mechanical ventilation of metformin group was lower than non-metformin group. In the multivariate model, metformin use was linked to a decreased in-hospital mortality and invasive mechanical ventilation when compared with that of the control group (HR: 0.376 [95% CI 0.154–0.922]; P = 0.033). CONCLUSION: Our study indicated that metformin therapy was associated with decreased death risk in COVID-19 patients with T2D.